B6;129S1-Vcam1^tm1Roml/J

Stock number: 002992
Product name: VCAM-1 KO
Research areas: Cardiovascular Research

Description

These Vcam1 knock-out mice exhibit a defect in placental development upon early embryonic death or heart abnormalities if surviving to later embryonic development. They are suitable for use in applications related to the study of placenta and heart dvelopment.

Detailed description

Mice homozygous for the Vcam1^tm1Roml targeted mutation are not viable and exhibit either of two phenotypes. Approximately half the VCAM-deficient embryos die prior to embryonic day 11.5 exhibiting a severe defect in placental development in which the allantois failed to fuse with the chorion. The other half of the VCAM-deficient embryos survive to embryonic day 11.5-12.5 and display several heart abnormalities. Significant amounts of blood is found in the heart and pericardial space and embyros lack an epicardium.

Development

The strain was developed by disruption of the murine Vcam gene by targeted homologous recombinationin ES cells and the introduction of the mutant ES cells into host blastocysts. The targeting vector introduced a frame shift and deletion mutation into the Vcam locus. In addition, a PGKneo resistance cassette was inserted within the coding region of the first Ig domain (exon 2). The construct was electroporated into 129S1/Sv-Oca2⁺ Tyr⁺ Kitl⁺-derived W9.5 embryonic stem (ES) cells. Correctly targeted ES cells were injected into blastocysts and resulting chimeric mice were bred to C57BL/6 mice.

Allele

Symbol: Vcam1^tm1Roml
Name: targeted mutation 1, Mark A Labow
MGI accession ID: MGI:1857452
Generation method: Targeted
Attributes: Null/Knockout
Synonyms: VCAM-1 -
Marker symbol: Vcam1
Marker name: vascular cell adhesion molecule 1
Marker synonyms: CD106; INCAM-100; Vcam-1; VCAM1B
Chromosome: 3
Strain of origin: 129S1/Sv-Oca2⁺ Tyr⁺ Kitl⁺
Molecular note: A PGK-neomycin resistance expression cassette replaced a genomic fragment containing part of exon 2 and exons 3-5. These sequences encode the Ig domains.